{"doi":"10.1007/s13277-016-4812-9","title":"Potential biomarker for checkpoint blockade immunotherapy and treatment strategy","abstract":null,"journal":"Tumor Biology","year":2016,"id":608700,"datarank":0.6749714505495399,"base_score":4.499809670330265,"endowment":4.499809670330265,"self_citation_contribution":0.6749714505495399,"citation_network_contribution":0.0,"self_endowment_contribution":0.6749714505495399,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":89,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1563645,"name":"Si-Pei Wu","orcid":null,"position":1,"is_corresponding":false},{"id":1563646,"name":"Ri-Qiang Liao","orcid":null,"position":2,"is_corresponding":false},{"id":1563647,"name":"Shu-Mei Huang","orcid":null,"position":3,"is_corresponding":false},{"id":1511765,"name":"Yi-Long Wu","orcid":null,"position":4,"is_corresponding":false},{"id":1563644,"name":"Zhong-Yi Dong","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Potential biomarker for checkpoint blockade immunotherapy and treatment strategy","abstract":"Programmed cell death protein-1 (PD-1) and ligand (PD-L1) provide an important escape mechanism from immune attack, and blockade therapy of these proteins show promising clinical benefits in many types of cancer. PD-L1 can be induced by interferon-gamma (IFN-γ), hypoxia, or toll-like receptor (TLR)-mediated pathways that confer adaptive immune resistance, or upregulated by oncogenic signals leading to constitutive expression and resulting in intrinsic immune resistance. The PD-1/PD-L1 checkpoint blockade, which targets regulatory pathways in T cells to overcome immune resistance, is correlated to PD-L1 expression pattern and the presence of tumor-infiltrating lymphocytes (TILs). Meanwhile, immunogenic mutation loads show significant response to checkpoint blockade, which is probably due to PD-1/L1 status and TIL content. Finally, the clinical strategies to design effective checkpoint-targeting immunotherapies are based on the classification of inducible/constitutive expression of PD-L1 and the presence of TILs.","is_dataset_classified":null,"base_score":4.499809670330265,"endowment":4.499809670330265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26779629","pmcid":null,"openalex_id":"https://openalex.org/W2240760035","authors":[],"funders":[{"funder_name":"Key Technologies Research and Development Program of Guangzhou","grant_id":"2011Y2-00014","title":null},{"funder_name":"Key Laboratory Program of Guangdong","grant_id":"2012A061400006","title":null},{"funder_name":"Special Fund for Research in the Public Interest from the National Health and Family Planning Commission of the People’s Republic of China","grant_id":"201402031","title":null}],"total_grants":3,"fwci":5.9034,"citation_percentile":0.97492557,"influential_citations":0,"citation_trend":[{"year":2016,"count":8},{"year":2017,"count":9},{"year":2018,"count":9},{"year":2019,"count":15},{"year":2020,"count":9},{"year":2021,"count":15},{"year":2022,"count":8},{"year":2023,"count":5},{"year":2024,"count":5},{"year":2025,"count":5},{"year":2026,"count":1}],"oa_status":"closed","license":"http://www.springer.com/tdm","oa_locations":[{"url":"http://link.springer.com/content/pdf/10.1007/s13277-016-4812-9.pdf","host_type":"publisher"},{"url":"http://link.springer.com/article/10.1007/s13277-016-4812-9/fulltext.html","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1007/s13277-016-4812-9","host_type":"publisher"},{"url":"https://doi.org/10.1007/s13277-016-4812-9","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26779629","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","CAR-T cell therapy research","Immune cells in cancer","B7-H1 Antigen","Biomarkers, Tumor","Cell Cycle Checkpoints","Gene Expression Regulation, Neoplastic","Humans","Immunotherapy","Interferon-gamma","Lymphocytes, Tumor-Infiltrating","Neoplasms","Programmed Cell Death 1 Receptor","T-Lymphocytes","Toll-Like Receptors"],"mesh_terms":["Humans","Immunotherapy","Interferon-gamma","Neoplasms","T-Lymphocytes","Biomarkers, Tumor","Gene Expression Regulation, Neoplastic","Lymphocytes, Tumor-Infiltrating","Toll-Like Receptors","Cell Cycle Checkpoints","B7-H1 Antigen","Programmed Cell Death 1 Receptor"],"keywords":["Blockade","Immune checkpoint","Immunotherapy","PD-L1","Cancer research","Immune system","Downregulation and upregulation","Cancer immunotherapy","T cell","Biology","Immunology","Receptor","Gene","TILs","Treatment Strategy","Checkpoint Blockade","Immune Resistance"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T20:30:46.629730Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}